All News

guidelines.recommendations.jpg

Is Your Practice Up to Date? New Guidelines for SLE Nephritis

d Michael Putman, MD, MSCI

Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate mofetil over cyclophosphamide.

Read Article
search bar

ICYMI: How Online Searches Reveal Patient Needs

d Bella Mehta, MBBS, MS

Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and treatment-related searches for rheumatic conditions.

Read Article
RA Treatment Adherence: Is decision making really shared? Dr. Jonathan Kay interviews Dr. Cécile Gaujoux-Viala about abstract 0360 at #ACR24. https://t.co/KwXHutfQko https://t.co/bCVM3JrFEz

Links:

Dr. John Cush RheumNow ( View Tweet)
Treat-to-Target Improves Fertility in Women with RA Dr. Richard Conway discusses abstract 1647, presented at #ACR24 https://t.co/vC0CA0lN4M https://t.co/Dfo7iBYwcU

Links:

Dr. John Cush RheumNow ( View Tweet)
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24 https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii

Links:

Dr. John Cush RheumNow ( View Tweet)
ORAL Surveillance - Is Statin Use the Problem/Solution? The findings from ORAL Surveillance Study have been a dominant conversation at #ACR24, with the seminal findings and subsequent analyses a target of debate. https://t.co/Nn9KSL4dlv https://t.co/gHPwK35eEd

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR24: What Exactly do JAKs and TYKs Do? Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly.… https://t.co/HkhZJBxDdO https://t.co/xYeSpHS2dD
Dr. John Cush RheumNow ( View Tweet)
Addressing CV Risk in RA: Are we doing enough? The increased risk of cardiovascular disease in patients with rheumatoid arthritis has long been known (1). #ACR24 https://t.co/dajYuK8rpd https://t.co/2Ds3OZEjUX

Links:

Dr. John Cush RheumNow ( View Tweet)
Apremilast Benefits and Risks in PsA Dr. Akhil Sood discusses abstracts 1466, 2583, 0598 and 2640 discussing the use of apremilast in PsA, presented at #ACR24. https://t.co/SSEeR9Xt9B https://t.co/cUeSUQoRsO

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR24 BEST Abstracts from Day 2 Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty. https://t.co/9qiPhemEPl https://t.co/uGQEiCcfah

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR24 - Day 2 Report Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024. https://t.co/TEWW0mDyl8 https://t.co/mZuqayonPN

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA For years, rheumatologists have championed weight loss as a cornerstone of care for patients with rheumatoid arthritis (RA) and obesity. RA is an independent risk factor for cardiovascular disease (CVD), a… https://t.co/iozo0FQFzj https://t.co/93e4nZMHJo
Dr. John Cush RheumNow ( View Tweet)
RheumNow Day 2 Recap: #ACR24 Highlights Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.… https://t.co/F3rZzOTiSJ https://t.co/t3wROMBe7D
Dr. John Cush RheumNow ( View Tweet)

RA: One JAK to Rule Them All? Dr. Brian Jaros reports on abstract 1362, presented at #ACR24. https://t.co/QChMyma3Y2 https://t.co/qq3BqpT2Gh

Links:

Dr. John Cush RheumNow ( View Tweet)
Transplant-free Survival Predictors in Idiopathic Inflammatory Myopathies-ILD Dr. Gaby Martinez discusses abstract 0333, Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease, presented at #ACR24.… https://t.co/3TSZ6PvZsD https://t.co/DLdzzfXhhp
Dr. John Cush RheumNow ( View Tweet)
Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis Dr. Antoni Chan interviews Dr. Catherine Bakewell on the Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis, at #ACR24. https://t.co/iCwNsuo7xz @synovialjoints https://t.co/Tjx3CE27TK

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA Potpourri Dr. Arthur Kavanaugh reviewed highlights on adult and pediatric sessions on uveitis, as well as interesting abstracts, at #ACR24 https://t.co/jsCMKHBFMk https://t.co/roZOZT3Mqd

Links:

Dr. John Cush RheumNow ( View Tweet)

JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P

Dr. John Cush RheumNow ( View Tweet)

Where there’s smoke, there’s flare: how pollution fuels RA The World Health Organisation (WHO) has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 (1, 2)… https://t.co/hmXPa492Qr https://t.co/BBClCplk8Z

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×